Cochrane · systematic review · CD013750
Platinum‐containing regimens for triple‐negative metastatic breast cancer
Egger, SJ, Chan, MM, Luo, Q, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 0 · 0%Very low 1 · 10%Low 5 · 50%Moderate 3 · 30%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Platinum compared to non‐platinum regimens for metastatic triple‐negative breast cancer: OS, PFS/TTP and OTRR
Population: women with metastatic triple‐negative breast cancer (mTNBC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Platinum vs non‐platinum regimens | HR 0.85 [0.73, 1] | 6 studies · 958 participants | Moderate Downgraded: imprecision, inconsistency, indirectness, publication bias |
Progression‐free survival/time to progression (PFS/TTP) Platinum vs non‐platinum regimens | HR 0.77 [0.68, 0.88] | 8 studies · 1077 participants | Very low Downgraded: imprecision, inconsistency, indirectness, publication bias |
Objective tumour response rate (OTRR) (assessable participants) Platinum vs non‐platinum regimens | RR 1.4 [1.22, 1.59] | 10 studies · 1205 participants | Low Downgraded: imprecision, inconsistency, indirectness, publication bias |
Platinum‐containing regimens and toxicity profile
Population: women with metastatic triple‐negative breast cancer (mTNBC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment‐related death (safety population) | RR 1.06 | 5 studies · 843 participants | Low Downgraded: imprecision, inconsistency |
Nausea/vomiting* grade 3 or 4 (safety population) | RR 4.77 | 3 studies · 655 participants | Low Downgraded: imprecision, inconsistency |
Nephrotoxicity (safety population) | no estimate extracted | NR | No studies |
Anaemia grade 3 or 4 (safety population) | RR 3.8 | 5 studies · 843 participants | Low Downgraded: imprecision, inconsistency |
Hair loss (safety population) | RR 0.33 | 2 studies · 602 participants | Low Downgraded: imprecision, inconsistency |
Leukopaenia (safety population) | RR 1.09 | 5 studies · 843 participants | Moderate Downgraded: imprecision, inconsistency |
Treatment discontinuation due to adverse event (safety population) | RR 0.88 | 5 studies · 843 participants | Moderate Downgraded: imprecision, inconsistency |